Evidence map›Paper›PMID 35263356›Full record

ArticlePloS one2022

Prediction of prognosis in immunoglobulin a nephropathy patients with focal crescent by machine learning.

Xuefei Lin, Yongfang Liu, Yizhen Chen, Xiaodan Huang, Jundu Li, Yuansheng Hou, Miaoying Shen, Zaoqiang Lin, Ronglin Zhang, Haifeng Yang and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Xuefei LinSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Yongfang LiuDepartment of Nephrology, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, China.
Yizhen ChenSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Xiaodan HuangSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Jundu LiSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Yuansheng HouSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Miaoying ShenSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Zaoqiang LinSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Ronglin ZhangSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Haifeng YangDepartment of Pathology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.
Songlin HongFane Data Technology Corporation, Tianjin, China.
Xusheng LiuDepartment of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.
Chuan ZouDepartment of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.ORCID 0000-0002-3182-7276
Guangzhou University of Chinese Medicine · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNJiujiang First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesImmunoglobulin a nephropathy (IgAN) is the most common primary glomerular disease in the world, with different clinical manifestations, varying severity of pathological changes, common complications of crescent formation in different proportions, and great individual heterogeneous in clinical outcomes. Therefore, we aim to develop a machine learning (ML) based predictive model for predicting the prognosis of IgAN with focal crescent formation and without obvious chronic renal lesions (glomerulosclerosis <25%). MATERIALS: We retrospectively reviewed biopsy-proven IgAN patients in our hospital and cooperative hospital from 2005 to 2017. The method of feature importance of random forest (RF) was applied to conduct feature exploration of feature variables to establish the characteristic variables that are closely related to the prognosis of focal crescent IgAN. Multiple ML algorithms were attempted to establish the prediction models. The area under the precision-recall curve (AUPRC) and the area under the receiver operating characteristic curve (AUROC) were applied to evaluate the predictive performance via three-fold cross validation (namely 2 training sets and 1 validation set).

resultsRF was used to screen the important features, the top three of which were baseline estimated glomerular filtration rate (eGFR), serum creatine and triglyceride. Ten important features were selected as important predictors for modeling on the basis of data-driven and medical selection, predictors include: age, baseline eGFR, serum creatine, serum triglycerides, complement 3(C3), proteinuria, mean arterial pressure (MAP) and Hematuria, crescents proportion of glomeruli, Global crescent proportion of glomeruli. In a variety of ML algorithms, the support vector machine (SVM) algorithm displayed better predictive performance, with Precision of 0.77, Recall of 0.77, F1-score of 0.73, accuracy of 0.77, AUROC of 79.57%, and AUPRC of 76.5%.

conclusionsThe SVM model is potentially useful for predicting the prognosis of IgAN patients with focal crescent shape and without obvious chronic renal lesions.

Indexed as

Glomerulonephritis, IGACreatineFemaleHumansMachine LearningMalePrognosisRetrospective StudiesCreatine

Identifiers

PMID35263356
PMCPMC8906594
OpenAlexW4220682722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.